Seres Therapeutics (MCRB) Misses Q2 EPS by 5c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
August 2, 2018 7:00 AM EDT- Company preparing to initiate SER-287 Phase 2b study for ulcerative colitis -
- Initiation of SER-401 clinical study expected in patients with metastatic melanoma treated with checkpoint inhibitors by year end -
- Recent Seres R&D event highlighted microbiome scientific leadership across several clinical and preclinical programs -
- Conference call at 8:30 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
